TERN
Terns Pharmaceuticals, Inc.
- Latest sale
- $50k
- Apr 1 · No plan
- Form 4 sales
- 21
- On record
- Form 144 notices
- 0
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planOct 1 2025
Sold 944 shares at $7.85 ($7k)
Kuriakose Emil, Chief Medical Officer
No 10b5-1 planSold 1.8% of holdings ($412k position)51,520 shares left1x usual sizeFiling
- 2 Form 4 saleRoutineNov 4 +34 days
Sold 24,520 shares at $18.00 ($441k)
Quigley Jill M., Director
10b5-1 planSold 100% of holdings ($441k position)0 shares left1.6x usual sizeFiling
- 3 Form 4 saleNo planJan 2 +59 days
Sold 1,155 shares at $38.57 ($45k)
Kuriakose Emil, Chief Medical Officer
No 10b5-1 planSold 2.2% of holdings ($2M position)50,365 shares left1.2x usual sizeFiling
- 4 Form 4 saleUnusualJan 5 +3 days
Sold 71,339 shares at $38.10 ($2.7M)
Burroughs Amy L., Chief Executive Officer
No 10b5-1 planSold 33.9% of holdings ($8M position)138,976 shares leftFirst sale on recordFiling
- 5 Form 4 saleRoutineJan 15 +10 days
Sold 68,749 shares at $37.08 ($2.5M)
Burroughs Amy L., Chief Executive Officer
10b5-1 planSold 19.2% of holdings ($13.3M position)288,976 shares leftFiling
- 6 Form 4 saleRoutineFeb 17 +33 days
Sold 14,583 shares at $39.20 ($572k)
Burroughs Amy L., Chief Executive Officer
10b5-1 planSold 4.8% of holdings ($11.9M position)288,976 shares leftFiling
- 7 Form 4 saleRoutineMar 16 +27 days
Sold 14,583 shares at $46.71 ($681k)
Burroughs Amy L., Chief Executive Officer
10b5-1 planSold 4.8% of holdings ($14.2M position)288,976 shares left0.2x usual sizeFiling
- 8 Form 4 saleNo planApr 1 +16 days
Sold 942 shares at $52.75 ($50k)
Kuriakose Emil, Chief Medical Officer
No 10b5-1 planSold 0.9% of holdings ($5.6M position)105,673 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (21)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 942 | $50k | 0.9% | No plan | SEC |
| Mar 16, 2026 | Burroughs Amy L. | Chief Executive Officer | Form 4 sale | 14,583 | $681k | 4.8% | Routine | SEC |
| Feb 17, 2026 | Burroughs Amy L. | Chief Executive Officer | Form 4 sale | 14,583 | $572k | 4.8% | Routine | SEC |
| Jan 15, 2026 | Burroughs Amy L. | Chief Executive Officer | Form 4 sale | 68,749 | $2.5M | 19.2% | Routine | SEC |
| Jan 5, 2026 | Burroughs Amy L. | Chief Executive Officer | Form 4 sale | 71,339 | $2.7M | 33.9% | Unusual | SEC |
| Jan 2, 2026 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 1,155 | $45k | 2.2% | No plan | SEC |
| Nov 4, 2025 | Quigley Jill M. | Director | Form 4 sale | 24,520 | $441k | 100.0% | Routine | SEC |
| Oct 1, 2025 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 944 | $7k | 1.8% | No plan | SEC |
| Jul 1, 2025 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 853 | $4k | 1.6% | No plan | SEC |
| Apr 1, 2025 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 952 | $2k | 1.8% | No plan | SEC |
| Jan 6, 2025 | Vignola Mark J. | Chief Financial Officer | Form 4 sale | 17,188 | $99k | 18.7% | Routine | SEC |
| Jan 6, 2025 | Quigley Jill M. | Director | Form 4 sale | 15,000 | $86k | 100.0% | Routine | SEC |
| Jan 2, 2025 | Kuriakose Emil | Chief Medical Officer | Form 4 sale | 4,481 | $26k | 7.6% | No plan | SEC |
| Sep 10, 2024 | Vignola Mark J. | Chief Financial Officer | Form 4 sale | 10,000 | $110k | 9.8% | Routine | SEC |
| Sep 9, 2024 | Quigley Jill M. | Director | Form 4 sale | 17,235 | $172k | 53.5% | Routine | SEC |
| Aug 2, 2024 | Quigley Jill M. | Director | Form 4 sale | 15,000 | $114k | 50.0% | Routine | SEC |
| Jul 16, 2024 | Quigley Jill M. | Director | Form 4 sale | 14,765 | $148k | 33.0% | Routine | SEC |
| Jul 16, 2024 | Gordon Carl L | Director, 10% owner | Form 4 sale | 56,164 | $562k | 6.9% | Routine | SEC |
| Jul 16, 2024 | OrbiMed Genesis GP LLC | Director, 10% owner | Form 4 sale | 56,164 | $562k | 6.9% | Routine | SEC |
| Apr 3, 2024 | Vivo Opportunity, LLC | 10% owner | Form 4 sale | 420,663 | $2.8M | 61.0% | Routine | SEC |
| Nov 23, 2022 | Oriental Spring Venture Ltd | 10% owner | Form 4 sale | 1.5M | $8.3M | 73.9% | Unusual | SEC |